TOPLINE: Adjuvant cisplatin-gemcitabine significantly improves progression-free survival (PFS) over standard cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. METHODOLOGY: The study included patients aged 18–65 years with untreated, nonkeratinizing, […]